Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 ARI-0001 cell therapy in relapsed or refractory CD19-positive acute lymphoblastic leukemia
2019-003038-17Phase 2Active
- Sponsor
- August Pi i Sunyer Biomedical Research Institute
- Start
- Nov 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ARI-0001 in acute lymphoblastic leukemia (ALL), sponsored by August Pi i Sunyer Biomedical Research Institute. Primary endpoint: Measurable residual disease-negative response rate at day 28. Started Nov 2020; status: active.
02
Drugs
ARI-0001
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2019-003038-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003038-17.